Goldstein Advisors 13F: Adds $265K to Merck (MRK) Stake

Goldstein Advisors has boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 41%, according to its latest Form 13F filing with the SEC. The firm added 1,824 shares during the reporting period, bringing its total holdings to 6,258 shares valued at approximately $909,350. This increase reflects Goldstein's confidence in Merck's prospects.

What Changed in Goldstein Advisors' Merck & Co. Position

Goldstein Advisors increased its holdings in Merck & Co. by 1,824 shares, a 41.1% rise from its previous count of 4,434 shares. The total value of this position is now about $909,350.

Merck & Co., Inc. Stock Up 1.1%

Shares of NYSE:MRK were not quoted for a specific price on Friday. Merck & Co. has a substantial market capitalization of $368.8 billion. The stock trades with a high P/E ratio of 119.6, but a more moderate forward P/E of 15.65, indicating expectations of future earnings growth. It has a beta of 0.226, suggesting lower volatility compared to the overall market. The stock's 52-week range is between $77.58 and $156.92. Its 50-day moving average is $138.39, while the 200-day moving average is $120.70. The company maintains a current ratio of 1.32 and a quick ratio of 0.74, with a debt-to-equity ratio of 128.41.

Recent Earnings

Merck & Co. reported revenues of approximately $66.57 billion, with a modest growth rate of 5.1%. The company achieved an earnings per share (EPS) of $1.25. Its net margin stands at 4.77%, and the return on equity (ROE) is 6.96%. The company is expected to release its next earnings report on October 29, 2026.

Dividend

Merck & Co. offers an annual dividend rate of $3.40 per share, yielding 2.31% based on its recent share price. The dividend payout ratio is 268.8%, indicating the percentage of earnings paid to shareholders in dividends.

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company based in Rahway, New Jersey. It is involved in the development and commercialization of pharmaceuticals for human and animal health. The company's product lineup includes treatments for various medical conditions under well-known brands like Keytruda and Gardasil. It also provides veterinary pharmaceuticals and vaccines. Merck is led by CEO Robert M. Davis and employs around 73,000 people worldwide.

Bottom Line

Goldstein Advisors' decision to increase its holdings in Merck & Co. underscores the firm's positive outlook on the healthcare giant. Investors often track these filings to gauge institutional sentiment. It's important to remember that 13F filings are backward-looking and may not reflect the investor's current position.